Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allegovac depot immunotherapy dosing in allergic rhinoconjunctivitis with or without asthma
2011-004583-30Phase 2Completed
- Sponsor
- BIAL
- Start
- Nov 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Allergovac Depot in allergic rhinoconjunctivitis (ARC), asthma and house dust mite allergy (6 arms), sponsored by BIAL. Started Nov 2011; status: completed.
02
Drugs
Allergovac Depot
03
Conditions
allergic rhinoconjunctivitis (ARC)asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2011-004583-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004583-30.